H
H.A. Aazami
Publications - 5
Citations - 162
H.A. Aazami is an academic researcher. The author has contributed to research in topics: Medicine & Triamcinolone acetonide. The author has an hindex of 2, co-authored 2 publications receiving 69 citations.
Papers
More filters
Journal ArticleDOI
Synovial and systemic pharmacokinetics (PK) of triamcinolone acetonide (TA) following intra-articular (IA) injection of an extended-release microsphere-based formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis (OA)
Virginia B. Kraus,P.G. Conaghan,H.A. Aazami,Purvi Mehra,Alan Kivitz,Joelle Lufkin,J. Hauben,J.R. Johnson,Neil Bodick +8 more
TL;DR: In knee OA patients, microsphere-based TA delivery via a single IA injection prolonged SF joint residency, diminished peak plasma levels, and thus reduced systemic TA exposure relative to TAcs.
Journal ArticleDOI
Efficacy and Safety of a Recombinant Plant-Based Adjuvanted Covid-19 Vaccine
Karen Hager,Gonzalo Pérez Marc,Philipe Gobeil,Ricardo Sobhie Diaz,Gretchen M. Heizer,Conrado J. Llapur,Alexander I. Makarkov,Eduardo Vasconcellos,Stéphane Pillet,F Riera,Pooja Saxena,Priscila Geller Wolff,Kapil Bhutada,Garry Wallace,H.A. Aazami,Christine E. Jones,Fernando P. Polack,Luciana Ferrara,Judith Atkins,Iohann Boulay,Jiwanjeet Dhaliwall,Nathalie Charland,Manon Couture,J. Jiang-Wright,Nathalie Landry,Sophie Lapointe,Aurélien Lorin,Asif Mahmood,Lawrence H. Moulton,Emily Pahmer,Julie Parent,Annie Séguin,Luan Tran,Thomas Breuer,Maria Angeles Ceregido,Marguerite Koutsoukos,François Roman,Junya Namba,Marc-André D'Aoust,Sonia Trépanier,Yosuke Kimura,Brian J. Ward +41 more
TL;DR: The CoVLP+AS03 vaccine was effective in preventing Covid-19 caused by a spectrum of variants, with efficacy ranging from 69.5% against symptomatic infection to 78.8% against moderate-to-severe disease.
Posted ContentDOI
Efficacy and Safety of a Plant-Based Virus-Like Particle Vaccine for COVID-19 Adjuvanted with AS03
Katrin Hager,Gonzalo Pérez Marc,Philipe Gobeil,Raúl² Silva Díaz,Gretchen M. Heizer,Conrado J. Llapur,Alexander I. Makarkov,E. Vasconcellos,Stéphane Pillet,F Riera,K. Bhutada,Patrice Wolff,Greg Wallace,H.A. Aazami,Caroline E. Jones,Fernando P. Polack,J. D. Atkins,Iohann Boulay,Jiwanjeet Dhaliwall,Nathalie Charland,Michele Couture,J. Jiang-Wright,Nathalie Landry,S. Lapointe,Aurélien Lorin,Asif Mahmood,Lawrence H. Moulton,Emmy Pahmer,Jason Parent,P. Saxena,Annie Séguin,Lillian Tran,Thomas Breuer,Maria Angeles Ceregido,Marguerite Koutsoukos,François Roman,J. Namba,Marc-André D'Aoust,Sonia Trépanier,Yoshiaki Kimura,The CoVLP Study Team,Brian J. Ward +41 more
TL;DR: The primary efficacy endpoint was prevention of symptomatic SARS-CoV-2 infection with onset at least 7 days after the second injection and was triggered by the identification of [≥]160 virologically-confirmed cases, and tolerability and safety of CoVLP+AS03 were also determined.
Journal ArticleDOI
Synovial and systemic pharmacokinetics of triamcinolone acetonide following intra-articular injection of an extended release formulation (FX006) or standard crystalline suspension in patients with knee osteoarthritis
V. Byers-Kraus,H.A. Aazami,Purvi Mehra,Alan Kivitz,Joelle Lufkin,J. Hauben,J.R. Johnson,Neil Bodick +7 more
Journal ArticleDOI
Efficacy and Safety of Ciprofloxacin Plus Fluocinolone Acetonide Among Patients With Acute Otitis Externa: A Randomized Clinical Trial.
Laurence Chu,Ana Maria Acosta,H.A. Aazami,Patrick B Dennis,Oscar De Valle,Dale Ehmer,James Hedrick,John F. Ansley +7 more
TL;DR: A statistically faster resolution of otalgia was achieved among patients treated with ciprofloxacin plus fluocinolone, and microbiological intent-to-treat population with Pseudomonas aeruginosa and Staphylococcus aureus.